T
Toregem BioPharma
Tooth regeneration medicine from Kyoto University — grow teeth with an injection
About Toregem BioPharma
Toregem BioPharma Co., Ltd. is a Kyoto University venture founded in May 2020 to research, develop, and commercialize tooth regeneration medicine based on the work of CTO Katsu Takahashi. The company is developing a neutralizing antibody approach that suppresses molecules inhibiting tooth-bud growth, aiming for the world's first injectable medicine that grows a patient's own teeth. Near-term focus is congenital edentulism; longer term the company targets tooth loss from decay and periodontal disease to extend healthy lifespan through retained natural dentition. Headquarters: Kamigyo-ku, Kyoto, Japan. Official site: https://toregem.co.jp/en/
Source: Dealroom company dataAt a glance
- Founded
- 2020
- Headquarters
- Kyoto, Japan
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Kyoto University Innovation CapitalKyogin Lease & Capital
Series A14 investors entered at this stage
Astellas Venture
Future Venture Capital- KCKyoshin Social Capital
Gemseki- STSanyo Trading
Tohoku University Venture Partners
Taisho Pharmaceutical
JIC Venture Growth Investments
Mitsubishi UFJ Capital- GCGreen Core
SIIF Impact Capital
Osaka University Venture Capital
Shofu- CCChushin Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Toregem BioPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Toregem BioPharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.